Neotract raises $23.7M to treat urological and gynecological disorders
Neotract, maker of devices used to treat urological and gynecological disorders, has raised $23.73 million of a targeted $25.2 million second round of funding according to PE Hub. Based in Pleasanton, Calif., the company was backed in this round by Johnson & Johnson Development Corp. and New Enterprise Associates.
Next Story: Oh great. Hackers can take over your iPhone with a text message
Previous Story: Pain treatment maker TorreyPines saved by Raptor merger
About the Author, Camille Ricketts
Camille is the lead writer for GreenBeat. She came to VentureBeat from Google where she worked on its traditional platforms team, particularly in TV. Before that, she was a reporter for the Wall Street Journal in New York and London. Follow her on Twitter at @camillericketts, and follow VentureBeat on Twitter at @venturebeat.
With GreenBeat 2009, VentureBeat's all-star conference on all things Smart Grid, coming up in November, Camille will be expanding coverage of this exciting space. Stay up to date by following @greenbeat2009 on Twitter or by becoming a fan of the event on Facebook here.